Previously, a somatic JAK2 mutation was found in a high number of myeloproliferative neoplasm (MPN) patients, that is, nearly 100% of patients with polycythemia vera (PV) and about 50% of patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF). Here, JAK2 is linked to acquired polycythemia vera.